• 한국식품저장유통학회지
• /
• 제24권2호
• /
• pp.289-293
• /
• 2017

버려지는 마늘껍질의 자원으로써의 활용 가치를 확인하기 위해 마늘껍질 70% 에탄올 추출물(GPE)을 이용하여 인체에서 유래된 폐암 세포(A549), 위암 세포(AGS), 유방암 세포(MCF-7), 간암 세포(Hep3B) 및 대장암 세포(HT-29)의 생존율에 미치는 영향을 확인하였다. 폐암 세포(A549)의 경우 $200{\mu}g/mL$의 저 농도에서는 A549 세포의 생존율이 100%로 증식 억제 효과가 나타나지 않았으나 $500{\mu}g/mL$ 이상의 농도에서는 A549 세포의 생존율이 10% 이하로 떨어지면서 우수한 폐암 세포 증식 억제활성이 확인되었다. 위암 세포에 대한 조사에서는 $1,000{\mu}g/mL$의 농도에서 55%의 생존율을 확인할 수 있었고, 최고 $2,000{\mu}g/mL$의 농도에서 71%의 위암 세포 증식 억제활성이 확인되었다. 유방암 세포(MCF-7)의 경우 $200{\mu}g/mL$의 저 농도에서 78%, $500{\mu}g/mL$ 이상의 농도 처리 결과에서는 모두 90% 전후의 유방암 세포 증식 억제활성이 확인되었다. 간암 세포의 경우 $100{\mu}g/mL$의 저 농도에서도 57%의 억제 활성이 확인되어, GPE의 매우 우수한 간암 세포 증식 억제 활성이 확인되었고, 처리되는 GPE의 농도가 증가함에 따라 $500{\mu}g/mL$ 농도까지 농도 의존적으로 간암 세포에 대한 증식 억제 활성은 증가되어 간암 세포의 생존율이 13%까지 저하되었다. 대장암 세포(HT-29)의 경우 $200{\mu}g/mL$의 저 농도 처리에서 15%, $500{\mu}g/mL$ 농도 처리에서 85%, $1,000{\mu}g/mL$의 고농도 처리에서 93%의 간암세포 증식 억제율이 확인되었으며, 농도 의존적으로 간암 세포에 대한 생장 억제 효과가 있는 것으로 확인되었다. 이상의 결과를 종합해 볼 때 마늘껍질 70% 에탄올 추출물 GPE는 조사된 제일 낮은 농도($100{\mu}g/mL$)에서도 간암 세포의 증식을 57% 억제하는 우수한 활성이 확인되었고, $200{\mu}g/mL$의 저 농도 범위에서는 유방암과 간암 세포의 증식을 72-78% 억제하는 높은 활성이 확인되었으며, $500{\mu}g/mL$ 이상의 농도에서는 위암 세포를 제외한 조사된 4종류의 암세포(폐암, 유방암, 간암 및 대장암 세포)의 증식을 85-90% 억제하는 우수한 활성이 확인되었다. 본 연구의 결과를 통해 마늘 가공 과정에서 쓰레기로 버려지고 있는 마늘껍질은 70% 에탄올 추출을 통해 유방암(MCF-7), 폐암(A549), 위암(AGS), 유방암(MCF-7) 및 간암(Hep3B) 세포의 성장을 억제하는 활성 물질로서의 재활용 가치가 높은 것으로 확인되었다.

• 대한임상검사과학회지
• /
• 제47권4호
• /
• pp.161-167
• /
• 2015

정상인에서 장내세균은 숙주의 면역이나 영양 흡수를 돕지만, 때로는 기회감염균으로서 그들을 위협하기도 한다. 그 중 절대 혐기성 세균인 Bacteroides fragilis는 분비되는 장독소(enterotoxin)인 Bacteroides fragilis toxin (BFT)의 유무에 따라 non-enterotoxigenic B. fragilis (NTBF)와 enterotoxigenic B. fragilis (ETBF)로 나뉜다. ETBF는 가축 및 사람에서 설사 질환 및 대장 질환을 유발한다 그러나 때때로 ETBF를 가지고 있으나 증상이 없는 사람도 존재한다. ETBF는 염증성 설사 질환, 여행자 설사 환자의 대변에서 검출되어 주목 받고 있다. 또한, 몇몇 연구를 통해 inflammatory bowel disease (IBD)나 대장염 및 대장암 환자에서 ETBF가 증가한다는 것이 밝혀졌다. 일반 C57BL/6 마우스 및 germ-free 마우스, multiple intestinal neoplasia (Min) 마우스, 토끼, Mongolian gerbil 등 여러 동물 모델에서 ETBF가 IBD나 대장염, 대장암을 유발 또는 촉진한다는 것이 발표되었다. ETBF의 유일한 병원성 인자인 BFT는 E-cadherin의 분절을 유도하여 장상피 세포의 투과성을 높인다. 이어서 ${\beta}$-catenin 신호전달계가 활성화하여 장상피세포의 증식이 증가한다. 또한 ETBF의 감염은 일반 마우스에서 급성이나 만성의 대장염을 일으키고 Min 마우스에서 종양 형성을 촉진한다. 이는 Stat3에 의존한 $T_H17$ 면역반응의 활성화를 통해 일어난다. 현재 ETBF의 검출 방법에는 크게 BFT toxin assay와 몇 가지 PCR 방법이 있다. 최근 real-time PCR과 같은 분자진단학적 기법의 발달로 일반적인 PCR보다 더 정확한 ETBF의 검출이 가능하게 되었다. 이것을 이용하여 앞으로 실제 임상에서 ETBF와 대장염 및 대장암의 발달 관계에 대한 심도 깊은 연구가 이뤄질 것으로 본다.

• IMMUNE NETWORK
• /
• 제13권5호
• /
• pp.213-217
• /
• 2013

Enterotoxigenic Bacteroides fragilis (ETBF) is a human gut commensal bacteria that causes inflammatory diarrhea and colitis. ETBF also promotes colorectal tumorigenesis in the Min mouse model. The key virulence factor is a secreted metalloprotease called B. fragilis toxin (BFT). BFT induces E-cadherin cleavage, cell rounding, activation of the ${\beta}$-catenin pathway and secretion of IL-8 in colonic epithelial cells. However, the precise mechanism by which these processes occur and how these processes are interrelated is still unclear. E-cadherin form homophilic interactions which tethers adjacent cells. Loss of E-cadherin results in detachment of adjacent cells. Prior studies have suggested that BFT induces IL-8 expression by inducing E-cadherin cleavage; cells that do not express E-cadherin do not secrete IL-8 in response to BFT. In the current study, we found that HT29/C1cells treated with dilute trypsin solution induced E-cadherin degradation and IL-8 secretion, consistent with the hypothesis that E-cadherin cleavage causes IL-8 secretion. However, physical damage to the cell monolayer did not induce IL-8 secretion. We also show that EDTA-mediated disruption of E-cadherin interactions without E-cadherin degradation was sufficient to induce IL-8 secretion. Finally, we determined that HT29/C1 cells treated with LiCl (${\beta}$-catenin activator) induced IL-8 secretion in a dose-dependent and time-dependent manner. Taken together, our results suggest that BFT induced IL-8 secretion may occur by the following process: E-cadherin cleavage, disruption of cellular interactions, activation of the ${\beta}$-catenin pathway and IL-8 expression. However, we further propose that E-cadherin cleavage per se may not be required for BFT induced IL-8 secretion.

• Journal of Chest Surgery
• /
• 제33권1호
• /
• pp.60-67
• /
• 2000

Background: Microsatellites are short-tandem repeated uncleotide sequences present throughout the human genome. Alterations of microsatellites have been termed microsatellite instability(MI). It has been generally known that microsatellite instability detected in hereditary non-polyposis colorectal cancer (HNPCC) reflects genetic instability that is caused by impairments of DNA mismatch repair system regarding as a novel tumorigenic mechanism. A number of studies reported that MI occurred at varying frequencies in non-small cell lung carcinoma (NSCLC). However It has been unproven whether MI could be a useful market of genetic instability and have a clinical significance in NSCLC. Material and Method : We have examined whether MI can be observed in thirty NCSLC using polymerase chain reaction whether such alterations are associated with other molecular changes such as p53, K-ras and c-myc oncoproteins expression detected by immunohistochemical stain,. Result: MI(+) was observed in 16.6%(5/30) and MI(-) was 83.3% (25/30) Average age was 50$\pm$7.5 year-old in MI(+) group and 57$\pm$6.6 year-old in MI(-) group. Two year survival rate in MI(=) group (20% 1/5) was worse than MI(-) group (64% 16/25) with a statistic difference. (P=0.04) The positive rate of K-ras oncoprotein expression and simultaneous expression of 2 or 3 oncoproteins expression were higher in MI(+) group than MI(-) group with a statistic difference(P=0.05, P=0.01) Conclusion: From, these results the authors can conclude that MI is found in some NSCLC and it may be a novel tumorigenic mechanism in some NSCLC. We also conclude that MI could be used as another poor prognostic factor in NSCLS.

• BMB Reports
• /
• 제51권6호
• /
• pp.296-301
• /
• 2018

Mitochondrial DNA (mtDNA) mutations are often observed in various cancer types. Although the correlation between mitochondrial dysfunction and cancer malignancy has been demonstrated by several studies, further research is required to elucidate the molecular mechanisms underlying accelerated tumor development and progression due to mitochondrial mutations. We generated an mtDNA-depleted cell line, ${\rho}^0$, via long-term ethidium bromide treatment to define the molecular mechanisms of tumor malignancy induced by mitochondrial dysfunction. Mitochondrial dysfunction in ${\rho}^0$ cells reduced drug-induced cell death and decreased the expression of pro-apoptotic proteins including p53. The p53 expression was reduced by activation of nuclear $factor-{\kappa}B$ that depended on elevated levels of free calcium in $HCT116/{\rho}^0$ cells. Overall, these data provide a novel mechanism for tumor development and drug resistance due to mitochondrial dysfunction.

• Biomolecules & Therapeutics
• /
• 제23권1호
• /
• pp.39-44
• /
• 2015

Tolfenamic acid (TA) is a traditional non-steroid anti-inflammatory drug (NSAID) and has been broadly used for the treatment of migraines. Nuclear factor kappa B (NF-${\kappa}B$) is a sequence-specific transcription factor and plays a key role in the development and progression of inflammation and cancer. We performed the current study to investigate the underlying mechanisms by which TA suppresses inflammation focusing on NF-${\kappa}B$ pathway in TNF-${\alpha}$ stimulated human normal and cancer cell lines and lipopolysaccharide (LPS)-stimulated mouse macrophages. Different types of human cells (HCT116, HT-29 and HEK293) and mouse macrophages (RAW264.7) were pre-treated with different concentrations of TA and then exposed to inflammatory stimuli such as TNF-${\alpha}$ and LPS. Transcriptional activity of NF-${\kappa}B$, $l{\kappa}B-{\alpha}$-degradation, p65 translocation and mitogen-activated protein kinase (MAPK) activations were measured using luciferase assay and Western blots. Pre-treatment of TA repressed TNF-${\alpha}$- or LPS-stimulated NF-${\kappa}B$ transactivation in a dose-dependent manner. TA treatment reduced degradation of $l{\kappa}B-{\alpha}$ and subsequent translocation of p65 into nucleus. TA significantly down-regulated the phosphorylation of c-Jun N-terminal kinase (JNK). However, TA had no effect on NF-${\kappa}B$ signaling and JNK phosphorylation in HT-29 human colorectal cancer cells. TA possesses anti-inflammatory activities through suppression of JNK/NF-${\kappa}B$ pathway in different types of cells.

• 한국응용과학기술학회지
• /
• 제32권1호
• /
• pp.108-115
• /
• 2015

EtOH 추출법과 열수 추출법을 사용하여 빈카민 등의 빈카 알칼로이드 화합물을 함유한 빈카 마이너 추출물을 얻었다. 이들 추출물을 사용하여 비듬균, 효모, 그람양성 및 음성세균에 대한 항균활성을 측정 하였다. 비듬균(Malassezia furfur)에 대하여 표준물질인 빈카민과 EtOH 추출물은 항균활성을 보이지 않은 반면 열수 추출물은 항균활성을 나타내었다. 또한 열수 추출물은 그람양성 및 음성세균에 속하는 바실러스(Bacillus sp.)와 대장균(Escherichia coli)에 대해서도 항균활성을 나타내었다. 추출물의 세포독성은 HaCaT 세포(인간 케라티노사이트 세포), HT-29 세포(인간 결직장 선종암 세포), Raw 세포(인간 대식세포)를 대상으로 측정하였으며, 해당 세포들에 대해 특별한 세포독성은 발견 되지 않았다. 또한 형광기반의 탐색물질인 디클로로플루오신 디아세테이트(DCFDA)를 이용한 활성산소종을 측정하였다. 그 결과 HaCaT 세포와 HT-29 세포군에서 활성산소종의 형성이 약 20% 정도 증가하는 것을 알 수 있었다.

• Animal cells and systems
• /
• 제15권1호
• /
• pp.9-17
• /
• 2011

Colorectal cancer is the third leading cause of cancer-related death in Western countries. Chemotherapeutic agents with different mechanisms of action have shown an increase in cure rates. In the present study, we investigated the effect of a combination of low concentration of paclitaxel (taxol, 5 nM) and topoisomerase 1 inhibitor camptothecin (CPT) on HCT116 colon cancer cells. Although the viability of cells treated with taxol alone was similar to that of control cells, sequential treatment with taxol and CPT exhibited high cytotoxicity. However, the opposite sequence of treatment did not exert cytotoxic effects on HCT116 cells. This enhanced cytotoxicity of the sequential combination therapy was the result of mitotic arrest, which increased the level of $p21^{Cip1/WAF1}$ through the p38 mitogen-activated protein kinase (MAPK) pathway. Knockdown by $p21^{Cip1/WAF1}$ siRNA or treatment with a p38 inhibitor reduced the viability of cells sequentially exposed to taxol and CPT. Taken together, a low taxol concentration in combination with CPT induced mitotic arrest in HCT116 cells, leading to synergistic cell death through enhanced expression of $p21^{Cip1/WAF1}$ and p38 MAPK pathway. Therefore, taxol could playa role as a sensitizer of CPT in colon cancer cells.

• 동의생리병리학회지
• /
• 제20권6호
• /
• pp.1572-1575
• /
• 2006

Water extract from Cnidii Rhizoma (CRW) was tested for colon cancer chemopreventive activity by measuring the induction of phase II detoxification enzyme activity [quinone reductase (QR) and glutathione S-transferase (GST)] and glutathion (GSH) levels and ornithine decarboxylase (ODC) activity in cultured human colorectal adenocarcinoma HT-29 cells. CRW inhibited cell proliferation in cultured HT-29 cells. CRW induced QR activity in a dose-dependent manner in a concentration range of 0.1${\sim}$5.0 $mg/m{\ell}$. GST activity was also induced with the treatment of CRW in HT-29 cells. In addition GSH levels was increased with CRW. CRW inhibited ODC activity, a key enzyme of polyamine biosynthesis, which is enhanced in tumor promotion. These results suggest that CRW has colon cancer chemopreventive activity by increasing phase II enzyme activity and GSH levels and inhibiting ODC activity in vitro.

• Journal of Microbiology and Biotechnology
• /
• 제32권9호
• /
• pp.1086-1097
• /
• 2022

During the last decades, research and therapeutic methods in cancer treatment have been evolving. As the results, nowadays, cancer patients are receiving several types of treatments, ranging from chemotherapy and radiation therapy to surgery and immunotherapy. In fact, most cancer patients take a combination of current anti-cancer therapies to improve the efficacy of treatment. However, current strategies still cause some side effects to patients, such as pain and depression. Therefore, there is the need to discover better ways to eradicate cancer whilst minimizing side effects. Recently, immunotherapy, particularly immune checkpoint blockade, is rising as an effective anti-cancer treatment. Unlike chemotherapy or radiation therapy, immunotherapy has few side effects and a higher tumor cell removal efficacy depend on cellular immunological mechanisms. Moreover, recent studies suggest that tissue immune responses are regulated by their microbiome composition. Each tissue has their specific microenvironment, which makes their microbiome composition different, particularly in the context of different types of cancer, such as breast, colorectal, kidney, lung, and skin. Herein, we review the current understanding of the relationship of immune responses and tissue microbiome in cancer in both animal and human studies. Moreover, we discuss the cancer-microbiome-immune axis in the context of cancer development and treatment. Finally, we speculate on strategies to control tissue microbiome alterations that may synergistically affect the immune system and impact cancer treatment outcomes.